Updates in acquired aplastic anemia: Can we do more for our patients?

1. Passweg J, et al. The complete treatment algorithm for SAA, EBMT, 2012, 1-41.Search in Google Scholar

2. Sureda A, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015, Bone Marrow Transplantation (2015), 1-20.10.1038/bmt.2015.625798672Search in Google Scholar

3. Schrezenmeier et al. Aplastic Anemia- Diagnostics and Therapy of Acquired Aplastic Anemia, 2012, 1-15Search in Google Scholar

4. Passweg JR, et al. Aplastic Anemia: First-line Treatment by Immunosuppression and Sibling Marrow Transplantation, ASH, 2010.10.1182/asheducation-2010.1.3621239768Search in Google Scholar

5. Guinan E. Diagnosis and Management of Aplastic Anemia, ASH, 2011.10.1182/asheducation-2011.1.7622160015Search in Google Scholar

6. DeZern AE, Brodsky R. Clinical management of aplastic anemia, Expert Rev Hematol. 2011 Apr; 4(2): 221-230.10.1586/ehm.11.11313872821495931Search in Google Scholar

7. Locasciulli A, Oneto R, Bacigalupo A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT) Haematologica. 2007;92(1):11-18. Guidance for immunosuppressive therapy or bone marrow transplantation as first-line therapy.10.3324/haematol.1007517229630Search in Google Scholar

8. Lawler M, McCann SR, Marsh JC, et al. Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA. Br. J. Haematol. 2009;144(6):933-945.10.1111/j.1365-2141.2008.07533.x19183198Search in Google Scholar

9. Schrezenmeier H, Passweg JR, Marsh JC, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood. 2007;110:1397-1400.10.1182/blood-2007-03-081596193991017475907Search in Google Scholar

10. Kahl C, Leisenring W, Deeg HJ, et al. Cyclophosphamide and anti-thymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. Br. J. Haematol. 2005;130(5):747-751.10.1111/j.1365-2141.2005.05667.x16115132Search in Google Scholar

11. Bacigalupo A. Bone marrow transplantation for severe aplastic anemia from HLA identical siblings. Haematologica. 1999;84(1):2-4.Search in Google Scholar

12. Champlin RE, Perez WS, Passweg JR, et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood. 2007;109(10):4582-4585.10.1182/blood-2006-10-052308188549117272503Search in Google Scholar

13. Al-Zahrani H, Nassar A, Al-Mohareb F, et al. Fludarabine based conditioning chemotherapy for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia. Biol. Blood Marrow Transplant. 2010 DOI: 10.1016/j. bbmt.2010.08.013.Search in Google Scholar

14. Maury S, et al. Improving outcome of patients older than 30 years receiving HLAidentical sibling HSCT for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. Haematologica. 2009.10.3324/haematol.2009.006916273872719734425Search in Google Scholar

15. Srinivasan R, Takahashi Y, McCoy JP, et al. Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. Br. J. Haematol. 2006;133(3):305-314.10.1111/j.1365-2141.2006.06019.x16643433Search in Google Scholar

16. Deeg HJ, O'Donnell M, Tolar J, Agarwal R, Harris RE, Feig SA, et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood. 2006 Sep 1;108(5):1485-91.10.1182/blood-2006-03-005041189551516684959Search in Google Scholar

17. Maury S, Balere-Appert ML, Chir Z, Boiron JM, Galambrun C, Yakouben K, et al. Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient. Haematologica. 2007 May;92(5):589-96.10.3324/haematol.1089917488681Search in Google Scholar

18. Young N, Bacigalupo A, Marsh J. Aplastic Anemia: Pathophysiology and Treatment. Biol Blood Marrow Transplant. 2009 Sep 23.Search in Google Scholar

19. Viollier R, Passweg J, Gregor M, et al. Quality-adjusted survival analysis shows differences in outcome after immunosuppression or bone marrow transplantation in aplastic anemia. Ann. Hematol. 2005;84(1):47-55.Search in Google Scholar

20. Siegal D, Xu W, Sutherland R J Kuruvilla, J H Lipton, M Minden, H Messner, V Gupta. Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies. Bone Marrow Transplantation 2008; 42, 51 - 56.10.1038/bmt.2008.8818372907Search in Google Scholar

21. Locasciulli A, Oneto R, Bacigalupo A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT) Haematologica. 2007;92(1):11-18.Search in Google Scholar

22. Peinemann F, Grouven U, Kroger N, Pittler M, Zschorlich B, Lange S. Unrelated donor stem cell transplantation in acquired severe aplastic anemia: a systematic review. Haematologica. 2009;94(12):1732-1742.10.3324/haematol.2009.007583279193319648165Search in Google Scholar

23. Viollier R, Socie G, Tichelli A, et al. Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant. 2008;41(1):45-50. 10.1038/sj.bmt.170589417982502Search in Google Scholar

24. Bacigalupo A, Socie G, Lanino E, et al. Fludarabine, cyclophosphamide, anti-thymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party. Haematologica. 2010;95(6):976-982.10.3324/haematol.2009.018267287879720494932Search in Google Scholar

25. Gafter-Gvili A, Ram R, Gurion R, et al. ATG plus cyclosporine reduces all-cause mortality in patients with severe aplastic anemia-systematic review and meta-analysis. ActaHaematol. 2008;120(4):237-243.10.1159/00020340319246887Search in Google Scholar

26. Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of anti-thymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood. 1999;93(7):2191-2195.10.1182/blood.V93.7.2191Search in Google Scholar

27. Scheinberg P, Nunez O, Wu C, Young NS. Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolatemofetil. Br. J. Haematol. 2006;133(6):606-61110.1111/j.1365-2141.2006.06085.x16704434Search in Google Scholar

28. Kao SY, Xu W, Brandwein JM, et al. Outcomes of older patients (> or = 60 years) with acquired aplastic anaemia treated with immunosuppressive therapy. Br. J. Haematol. 2008;143(5):738-743.10.1111/j.1365-2141.2008.07389.x19062343Search in Google Scholar

29. Rosenfeld S, Follmann D, Nunez O, Young NS. Anti-thymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003;289(9):1130-1135. Randomized trial showing anti-thymocyte globulin and cyclosporine as combination immunosuppressive therapy.10.1001/jama.289.9.113012622583Search in Google Scholar

30. Scheinberg P, Nunez O, Wu C, Young NS. Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolatemofetil. Br. J. Haematol. 2006;133(6):606-611.10.1111/j.1365-2141.2006.06085.x16704434Search in Google Scholar

31. Gluckman E, Rokicka-Milewka R, Hann I, Nikiforakis E, Tavakoli F, Cohen-Scali S, Bacigalupo A. Results and follow-up of a phase III randomized study of recombinant humangranulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol. 2002;119(4):1075-82.10.1046/j.1365-2141.2002.03947.x12472591Search in Google Scholar

32. Ohara A, Kojima S, Hamajima N, et al. Myelodysplastic syndrome and acute myelogenousleukemia as a late clonal complication in children with acquired aplastic anemia. Blood. 1997;90(3):1009-1013.10.1182/blood.V90.3.1009Search in Google Scholar

33. Brodsky RA, Chen AR, Dorr D, et al. High-dose cyclophosphamide for severe aplastic anemia: long-term followup. Blood. 2010;115(11):2136-2141.10.1182/blood-2009-06-225375284402020018919Search in Google Scholar

34. Gómez-Almaguer D, Jaime-Pérez JC, Garza-Rodríguez V, Chapa-Rodríguez A, Tarín-Arzaga L, Herrera-Garza JL, Ruiz-Argüelles GJ, López-Otero A, González-Llano O, Rodríguez-Romo L. (2009) Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia. Annals of Haematology, DOI 10.1007/s00277-009-0816-5.Search in Google Scholar

35. Risitano AM, et al. on behalf of the Working Party Severe Aplastic Anemia (WPSAA) of the European Group for Blood and Marrow Transplantation (EBMT). Alemtuzumab Is Safe And Effective As Immunosuppressive Treatment For Aplastic Anemia And Single-Lineage Marrow Failure: A Pilot Study And A Survey From The EBMT WPSAA. British Journal of Haematology, 2010. 10.1111/j.1365-2141.2009.08027.x19995389Search in Google Scholar